All results - Drugs and Technologies - Prescribing and Technical Information - Safety Alerts - Medicines and Healthcare products Regulatory Agency - MHRA - East Midlands Academic Health Science Network | Evidence search

Click export CSV or RIS to download the entire page or use the checkboxes to select a subset of records to download

Letters sent to healthcare professionals in October 2016

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 08 November 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

A summary of recent safety letters sent to relevant healthcare professionals

Read Summary

- Remove: Prescribing and Technical Information filter
Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 17 October 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

Prescribing information has been updated to introduce a lower recommended dose of 60 mg daily for patients with rheumatoid arthritis or ankylosing spondylitis.

Read Summary

- Remove: Prescribing and Technical Information filter
Letters sent to healthcare professionals in September 2016, including retigabine withdrawal

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 17 October 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

A summary of letters sent to healthcare professionals in September 2016, including important information for professionals who specialise in epilepsy treatment regarding the withdrawal from the...

Read Summary

- Remove: Prescribing and Technical Information filter
Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 15 September 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

Medicines or herbal remedies that induce CYP3A4 enzymes reduce blood levels of levonorgestrel, which may reduce emergency contraceptive efficacy.

Read Summary

- Remove: Prescribing and Technical Information filter
Letters sent to healthcare professionals in February 2016

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 10 March 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

In February 2016, a letter was sent to healthcare professionals regarding medicines containing valproate.

Read Summary

- Remove: Prescribing and Technical Information filter
Valproate and risk of abnormal pregnancy outcomes: new communication materials

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 17 February 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

Children exposed to valproate in utero are at high risk of developmental disorders and congenital malformations. Use the new communication materials below to discuss these risks with patients

Read Summary

- Remove: Prescribing and Technical Information filter
Nicorandil (Ikorel): now second-line treatment for angina - risk of ulcer complications

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 21 January 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

Updated advice on use of nicorandil as second-line treatment for stable angina - some ulcers may progress to complications unless treatment is stopped.

Read Summary

- Remove: Prescribing and Technical Information filter
Yellow Card: please help to reverse the decline in reporting of suspected adverse drug reactions

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 17 May 2019 - Publisher: Medicines and Healthcare products Regulatory Agency

2018 saw a fall in reporting of suspected adverse drug reactions (ADRs) to the Yellow Card Scheme from key reporter groups, including GPs, pharmacists, and hospital doctors. Every Yellow Card report...

Read Summary

- Remove: Prescribing and Technical Information filter
Medical Device Alerts issued in September 2019

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 18 October 2019 - Publisher: Medicines and Healthcare products Regulatory Agency

Alerts were issued about T34 ambulatory syringe pumps, Gripper needles, and 1-day Acuvue Moist for astigmatism contact lenses.

Read Summary

- Remove: Prescribing and Technical Information filter
Lartruvo▼ (olaratumab): withdrawal of the EU marketing authorisation due to lack of efficacy

Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - Source: GOV UK - 19 June 2019 - Publisher: Medicines and Healthcare products Regulatory Agency

The ANNOUNCE study failed to show clinical efficacy for olaratumab in its current indication of advanced soft tissue sarcoma and the benefit risk balance is therefore now considered negative. No new...

Read Summary

- Remove: Prescribing and Technical Information filter

Filter results by

Results for all evidence | Drugs and Technologies | Prescribing and Technical Information | Medicines and Healthcare products Regulatory Agency - MHRA 61 - 70 of 1041 sorted by relevance / date

Letters sent to healthcare professionals in October 2016

Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis

Letters sent to healthcare professionals in September 2016, including retigabine withdrawal

Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers and contraceptive efficacy

Letters sent to healthcare professionals in February 2016

Valproate and risk of abnormal pregnancy outcomes: new communication materials

Nicorandil (Ikorel): now second-line treatment for angina - risk of ulcer complications

Yellow Card: please help to reverse the decline in reporting of suspected adverse drug reactions

Medical Device Alerts issued in September 2019

Lartruvo▼ (olaratumab): withdrawal of the EU marketing authorisation due to lack of efficacy